Resting-state Functional Connectivity Changes During Migraine Treatment
NCT ID: NCT03484871
Last Updated: 2020-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2016-05-31
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longitudinal Changes of Brain Functional Connectivity in Migraine
NCT03487978
Change in Connectivity After mTBI Depending on Cognitive Reserve
NCT05593172
Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura
NCT02564822
Magnetoencephalography (MEG), Attention and Conscience
NCT01592175
Structural and Molecular Neuroplasticity in Migraine
NCT03004313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In 30 migraineurs with 8-14days with headache per months who already performed brain magnetic resonance imaging will be recruited. Treatment medications such as frovatriptan and topiramate will be used for 6 months. After 6 months, follow-up brain magnetic resonance imaging will be performed.
The primary outcome is the longitudinal changes in functional connectivity in pain-processing/modulating brain regions. The secondary outcome is following: 1)longitudinal changes in structural and morphological alterations in brain regions of pain processing; 2)structural, morphological, and functional correlates of treatment response; 3)changes in monthly migraine days, migraine frequecies, headache days, and headache frequencies after treatment; 4)responses to acute migraine treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-50
* Drug-naïve high frequency episodic migraineurs (8-14 attacks/m)
* Performed a baseline interictal brain MRI
Exclusion Criteria
* Chronic pain other than migraine
* On treatment of major depression, bipolar, schizophrenia, or BDI\>25
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
SK Chemicals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chin-Sang Chung
MD, PhD, Professor of neurology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chin-Sang Chung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-04-028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.